Maharashtra Herald

DelveInsight’s “Moderate Psoriasis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Moderate Psoriasis, historical and forecasted epidemiology as well as the Moderate Psoriasis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Moderate Psoriasis Overview

Moderate psoriasis is when 3% to 10% of your body has patches. This usually means it affects your arms and legs, torso, and scalp. It’s also considered moderate if it can’t be controlled using a skin medication or if it has a significant impact on your quality of life. Moderate Psoriasis has both pediatric and adult-onset, with the former accounting for more number of cases. Plaques vary in terms of variable morphology, distribution, and severity.

Some of the key facts of the Moderate Psoriasis Market Report:  

• The Moderate Psoriasis market size is anticipated to grow with a significant CAGR during the study period (2019-2032) 
• The prevalence of psoriasis in England is estimated to be 1.75% , which is about  951,000 people, of whom about 15% have moderate psoriasis, equating to approximately 140,000 people 
• Psoriasis can present at any age and has been reported at birth and in older people of advanced age. Accurate determination of the age of onset of psoriasis is problematic 
• As per the German national program on psoriasis healthcare, about 400,000 patients (25 %) suffer from moderate to severe forms and thus show a particularly high need for intervention 
• Key Moderate Psoriasis Companies: UCB Pharma, Dermavant Sciences, Bristol Myers Squibb, Delenex Therapeutics AG, UCB Celltech, and others
• Key Moderate Psoriasis Therapies: Bimekizumab, Tapinarof, Deucravacitini, DLX105, UCB4940, and others
• The Moderate Psoriasis epidemiology based on gender analyzed that moderate psoriasis affects males slightly more than females 

Get a Free sample for the Moderate Psoriasis Market Report 

Key benefits of the Moderate Psoriasis Market report:

1. Moderate Psoriasis market report covers a descriptive overview and comprehensive insight of the Moderate Psoriasis Epidemiology and Moderate Psoriasis market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. The Moderate Psoriasis market report provides insights on the current and emerging therapies.
3. Moderate Psoriasis market report provides a global historical and forecasted market covering drug outreach in 7MM.
4. The Moderate Psoriasis market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Moderate Psoriasis market.

Discover more about therapies set to grab major Moderate Psoriasis market share @ Moderate Psoriasis market forecast

Moderate Psoriasis Epidemiology Segmentation:

The Moderate Psoriasis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Moderate Psoriasis
• Prevalent Cases of Moderate Psoriasis by severity
• Gender-specific Prevalence of Moderate Psoriasis
• Diagnosed Cases of Episodic and Chronic Moderate Psoriasis 

Moderate Psoriasis Market  

The dynamics of the Moderate Psoriasis market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Bimekizumab, Tapinarof, and others during the forecasted period 2019-2032. 

Download the report to understand which factors are driving Moderate Psoriasis epidemiology trends @ Moderate Psoriasis Epidemiological Insights 

Moderate Psoriasis Therapies and Key Companies

• Bimekizumab: UCB Pharma
• Tapinarof: Dermavant Sciences
• DeucravacitiniSquibb: Bristol Myers
• DLX105: Delenex Therapeutics AG
• UCB4940: UCB Celltech

Scope of the Moderate Psoriasis Market Report

• Study Period: 2019–2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Moderate Psoriasis Companies: UCB Pharma, Dermavant Sciences, Bristol Myers Squibb, Delenex Therapeutics AG, UCB Celltech, and others
• Key Moderate Psoriasis Therapies: Bimekizumab, Tapinarof, Deucravacitini, DLX105, UCB4940, and others
• Moderate Psoriasis Therapeutic Assessment: Moderate Psoriasis current marketed and Moderate Psoriasis emerging therapies
• Moderate Psoriasis Market Dynamics:  Moderate Psoriasis market drivers and Moderate Psoriasis market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Moderate Psoriasis Unmet Needs, KOL’s views, Analyst’s views, Moderate Psoriasis Market Access and Reimbursement 

Table of Contents 

1. Moderate Psoriasis Market Report Introduction

2. Executive Summary for Moderate Psoriasis

3. SWOT analysis of Moderate Psoriasis

4. Moderate Psoriasis Patient Share (%) Overview at a Glance

5. Moderate Psoriasis Market Overview at a Glance

6. Moderate Psoriasis Disease Background and Overview

7. Moderate Psoriasis Epidemiology and Patient Population

8. Country-Specific Patient Population of Moderate Psoriasis 

9. Moderate Psoriasis Current Treatment and Medical Practices

10. Moderate Psoriasis Unmet Needs

11. Moderate Psoriasis Emerging Therapies

12. Moderate Psoriasis Market Outlook

13. Country-Wise Moderate Psoriasis Market Analysis (2019–2032)

14. Moderate Psoriasis Market Access and Reimbursement of Therapies

15. Moderate Psoriasis Market Drivers

16. Moderate Psoriasis Market Barriers

17.  Moderate Psoriasis Appendix

18. Moderate Psoriasis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

To know more about Moderate Psoriasis treatment, visit @ Moderate Psoriasis Medications

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/